Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2025-10-16 Capital/Financing Update
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Xbrane Biopharma ingår villkorad finansieringslösning med Fenja Capital II A/S
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a new conditional financing agreement (a loan of 60 million SEK) between Xbrane Biopharma and Fenja Capital II A/S. It details the terms of the financing, the rationale behind it (securing capital in case of FDA approval delays), and contact information. Since the document describes a specific financing arrangement and capital structure change, it falls under the 'Capital/Financing Update' category. It is not a report publication announcement (RPA) because it provides the substantive details of the financing rather than just announcing the availability of a separate report.
2025-10-16 Swedish
Xbrane Biopharma enters into conditional financing solution with Fenja Capital II A/S
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a new conditional financing agreement (a loan of SEK 60 million) entered into by Xbrane Biopharma. It details the terms of the financing, including interest rates, maturity, and potential warrant issuance. This falls squarely under the definition of a capital or financing update. While it mentions an attachment, the text itself provides the full details of the transaction, making it a primary announcement rather than just a report publication notice.
2025-10-16 English
Record date for reverse share split in Xbrane Biopharma AB
Share Issue/Capital Change Classification · 100% confidence The document announces a reverse share split, which is a change to the company's capital structure. While it mentions an Extra General Meeting, the primary purpose of the document is to communicate the mechanics, timeline, and record date of the share consolidation (reverse split). This falls under the category of share capital changes.
2025-10-15 English
Avstämningsdag för sammanläggning av aktier i Xbrane Biopharma AB
Share Issue/Capital Change Classification · 100% confidence The document announces a reverse stock split (sammanläggning av aktier) for Xbrane Biopharma AB, detailing the ratio, record date, and impact on ISIN codes and share counts. This falls under corporate capital structure changes. While it mentions a 'Bifogade filer' (attached files) section, the document itself provides the substantive details of the corporate action rather than just announcing the availability of a separate report. Therefore, it is classified as a Share Issue/Capital Change announcement.
2025-10-15 Swedish
Announcement from extra general meeting in Xbrane Biopharma AB
AGM Information Classification · 100% confidence The document is an official announcement detailing the resolutions passed at an 'extra general meeting' (EGM) of Xbrane Biopharma AB. It covers specific corporate actions such as amendments to articles of association, a reverse share split, reduction of share capital, and authorization for the board to issue new shares. While it reports on the results of a meeting, it is not a full transcript or a formal voting results report (DVA) in the sense of a tally sheet, but rather a summary of the meeting's outcomes. Given the nature of the resolutions (share capital changes and reverse splits), it fits best under 'Share Issue/Capital Change' (SHA) as these are the primary corporate actions described.
2025-10-13 English
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
AGM Information Classification · 100% confidence The document is a 'Kommuniké från extra bolagsstämma' (Communiqué from an Extraordinary General Meeting) for Xbrane Biopharma AB. It details specific resolutions passed by shareholders, including amendments to the articles of association, a reverse stock split (1:125), capital reductions, and authorization for the board to issue new shares. While it mentions the meeting results, it is a formal announcement of the decisions made at the meeting, which falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-10-13 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.